EMPA-REG Outcome: results that question

被引：0
|
作者：
Pouchain, Denis [1 ]
机构：
[1] UFR Tours, Dept Univ Med Gen, Tours, France
来源：
EXERCER-LA REVUE FRANCOPHONE DE MEDECINE GENERALE | 2016年 / 27卷 / 128期
关键词：
Empagliflozin; Hypoglycemic agents; Randomized controlled trials;
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：278 / 282
页数：5
相关论文
共 50 条
  • [21] DECLARE-TIMI 58 TRIAL IN THE CONTEXT OF EMPA-REG OUTCOME AND CANVAS
    Shestakova, Marina, V
    DIABETES MELLITUS, 2019, 22 (06): : 592 - 601
  • [22] Implications of the EMPA-REG Trial for Clinical Care and Research
    Angeliki M. Stamatouli
    Silvio E. Inzucchi
    Current Diabetes Reports, 2016, 16
  • [23] Relationship between hypoglycaemia, cardiovascular outcomes, and empagilflozin treatment in the EMPA-REG OUTCOME® trial
    Fitchett, David
    Inzucchi, Silvio E.
    Wanner, Christoph
    Mattheus, Michaela
    George, Jyothis T.
    Vedin, Ola
    Zinman, Bernard
    Johansen, Odd Erik
    EUROPEAN HEART JOURNAL, 2020, 41 (02) : 209 - 217
  • [24] Generalizability of REDUCE-IT eligibility criteria in a large diabetes cardiovascular outcomes trial: A post hoc subgroup analysis of EMPA-REG outcome Analysis of EMPA-REG OUTCOME using REDUCE-IT criteria
    Verma, Subodh
    Kosmopoulos, Andrew
    Bhatt, Deepak L.
    Fitchett, David
    Ofstad, Anne Pernille
    Wanner, Christoph
    Mattheus, Michaela
    Zinman, Bernard
    Lawler, Patrick R.
    Leiter, Lawrence A.
    AMERICAN JOURNAL OF PREVENTIVE CARDIOLOGY, 2023, 15
  • [25] Reappraisal of the diuretic effect of empagliflozin in the EMPA-REG OUTCOME trial: Comparison with classic diuretics
    Scheen, A. J.
    DIABETES & METABOLISM, 2016, 42 (04) : 224 - 233
  • [26] Implications of the EMPA-REG Trial for Clinical Care and Research
    Stamatouli, Angeliki M.
    Inzucchi, Silvio E.
    CURRENT DIABETES REPORTS, 2016, 16 (12)
  • [27] Cost-effectiveness Analysis of Empagliflozin in Japan Based on Results From the Asian subpopulation in the EMPA-REG OUTCOME Trial
    Kaku, Kohei
    Haneda, Masakazu
    Sakamaki, Hiroyuki
    Yasui, Atsutaka
    Murata, Tatsunori
    Ustyugova, Anastasia
    Chin, Rina
    Hirase, Tetsuaki
    Shibahara, Tsunehisa
    Hayashi, Naoyuki
    Kansal, Anuraag
    Kaspers, Stefan
    Okamura, Tomoo
    CLINICAL THERAPEUTICS, 2019, 41 (10) : 2021 - 2040
  • [28] Reduction in cardiovascular and all-cause mortality in the EMPA-REG OUTCOME trial: A critical analysis
    Scheen, Andre J.
    DIABETES & METABOLISM, 2016, 42 (02) : 71 - 76
  • [29] Cardio/Kidney Composite End Points: A Post Hoc Analysis of the EMPA-REG OUTCOME Trial
    Ferreira, Joao Pedro
    Kraus, Bettina Johanna
    Zwiener, Isabella
    Lauer, Sabine
    Zinman, Bernard
    Fitchett, David H.
    Koitka-Weber, Audrey
    George, Jyothis T.
    Ofstad, Anne Pernille
    Wanner, Christoph
    Zannad, Faiez
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2021, 10 (07):
  • [30] Clinical Implications of Cardiovascular Outcome Trials in Type 2 Diabetes: From DCCT to EMPA-REG
    Ryden, Lars
    Shahim, Bahira
    Mellbin, Linda
    CLINICAL THERAPEUTICS, 2016, 38 (06) : 1279 - 1287
12345